GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance
GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.
How this was made

The 30-second read
Why it matters
The FDA clearance provides hard validation for the ALKOVE-1 Phase 1/2 results, but the accelerated pathway means investors will focus on confirmatory endpoints and whether Nelkarmi can displace alectinib in first-line settings via ALKAZAR.
Market read
This is a direct FDA regulatory catalyst for GSK’s oncology pipeline, with the next tradable inflection tied to confirmatory survival data and first-line trial outcomes.
What to watch
Commercial uptake may be constrained by biomarker-defined eligibility, prior-treatment sequencing, and payer scrutiny of accelerated-label evidence versus established ALK competitors.
Background
GSK acquired the Nelkarmi asset (neladalkib) via its $10.6B Nuvalent deal and is rebuilding its oncology portfolio after prior divestments.
Ticker impact
GSK received FDA accelerated approval for Nelkarmi (neladalkib) in ALK-mutated NSCLC after prior ALK therapy, adding a new US commercialization catalyst.
Likely positive bias as traders price in incremental revenue potential, tempered by uncertainty around confirmatory endpoints and first-line positioning.
The article is a first-time FDA clearance event for GSK’s drug, with explicit mention of accelerated pathway uncertainty and an ongoing Phase 3 first-line trial as the next key catalyst.
Market effects
Reinforces competitive intensity in ALK-positive NSCLC and highlights the value of next-generation ALK inhibitors with CNS penetration.
US regulatory approval can shift sentiment for European pharma oncology names with US commercialization exposure.
May affect global ALK NSCLC treatment sequencing expectations, especially around resistance mutation coverage and CNS activity.
Counterpoint
Accelerated approvals can underperform if confirmatory trials fail to show survival benefit, so the stock reaction may fade before ALKAZAR and confirmatory readouts.
Key entities
- companyGSK
Sponsor of Nelkarmi (neladalkib) and developer of the ALKAZAR Phase 3 first-line study.
- regulatorFDA
Granted accelerated clearance for Nelkarmi in ALK-mutated NSCLC after prior ALK-targeted therapy.
- drugNelkarmi (neladalkib)
Once-daily oral next-generation ALK inhibitor with CNS penetration intent; approved under accelerated pathway.
- clinical_trialALKOVE-1
Phase 1/2 trial supporting the accelerated approval, including response and duration metrics and intracranial activity.
- clinical_trialALKAZAR
Phase 3 trial testing Nelkarmi as first-line therapy versus alectinib.




